Clinical Trials for Neurocrine Biosciences

Explore 19 clinical trials worldwide

Showing 1-19 of 19 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: Neurocrine Biosciences

Clinical Trials (19)

NCT07111988
Valbenazine in Obsessive Compulsive Disorder
PHASE2Not yet recruiting
30 participants
Started: Oct 31, 2025 · Completed: Oct 31, 2027
1 condition2 sponsors0 locations
NCT07187375
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
PHASE2Not yet recruiting
6 participants
Started: Sep 28, 2025 · Completed: Oct 4, 2029
1 condition1 sponsor0 locations
NCT07105111
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
PHASE4Recruiting
50 participants
Started: Aug 29, 2025 · Completed: Apr 30, 2027
5 conditions1 sponsor8 locations
NCT07196501
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
PHASE3Recruiting
550 participants
Started: Aug 18, 2025 · Completed: Jul 31, 2028
1 condition1 sponsor4 locations
NCT07105098
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
PHASE3Recruiting
284 participants
Started: Aug 11, 2025 · Completed: Nov 30, 2027
1 condition1 sponsor5 locations
NCT07114874
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
PHASE3Recruiting
800 participants
Started: Jul 11, 2025 · Completed: Dec 31, 2031
1 condition1 sponsor24 locations
NCT06963021
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
PHASE3Recruiting
200 participants
Started: May 30, 2025 · Completed: Jul 31, 2027
1 condition1 sponsor9 locations
NCT06963034
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
PHASE3Recruiting
284 participants
Started: May 8, 2025 · Completed: Oct 31, 2027
1 condition1 sponsor16 locations
NCT06966401
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
PHASE3Recruiting
600 participants
Started: Apr 16, 2025 · Completed: May 31, 2030
1 condition1 sponsor18 locations
NCT06911112
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
PHASE3Recruiting
200 participants
Started: Mar 31, 2025 · Completed: Jul 31, 2027
1 condition1 sponsor1 location
NCT06786624
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
PHASE3Recruiting
200 participants
Started: Jan 22, 2025 · Completed: Jul 31, 2027
1 condition1 sponsor6 locations
NCT06312189
Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada
PHASE3Enrolling by invitation
7 participants
Started: Apr 24, 2024 · Completed: Apr 30, 2026
1 condition1 sponsor3 locations
NCT06267846
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
PHASE2Active, not recruiting
73 participants
Started: Mar 20, 2024 · Completed: Dec 31, 2025
1 condition1 sponsor13 locations
NCT05207085
Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults
PHASE2Recruiting
20 participants
Started: Feb 2, 2024 · Completed: Oct 15, 2026
1 condition2 sponsors1 location
NCT05226780
Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE
PHASE2Active, not recruiting
8 participants
Started: Jul 12, 2022 · Completed: Mar 31, 2026
1 condition1 sponsor4 locations
NCT05206513
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
PHASE3Active, not recruiting
86 participants
Started: Apr 15, 2022 · Completed: Jun 30, 2026
2 conditions1 sponsor38 locations
NCT04806451
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
PHASE3Active, not recruiting
103 participants
Started: Jun 25, 2021 · Completed: Aug 31, 2027
1 condition1 sponsor46 locations
NCT04490915
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
PHASE3Active, not recruiting
182 participants
Started: Dec 16, 2020 · Completed: Aug 31, 2027
1 condition1 sponsor70 locations
NCT04400331
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
PHASE3Active, not recruiting
154 participants
Started: Sep 18, 2020 · Completed: Mar 31, 2026
1 condition2 sponsors34 locations